Sandoz Group AG (SDZ) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Sandoz Group AG (SDZ) has a cash flow conversion efficiency ratio of 0.114x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CHF1.07 Billion ≈ $1.35 Billion USD) by net assets (CHF9.38 Billion ≈ $11.87 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See SDZ equity financing ratio to measure how much of total assets are equity-financed.
Sandoz Group AG - Cash Flow Conversion Efficiency Trend (2020–2025)
This chart illustrates how Sandoz Group AG's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check how high is Sandoz Group AG's earnings quality to evaluate the quality of earnings relative to operating cash generation.
Sandoz Group AG Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sandoz Group AG ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Nokia Oyj
HE:NOKIA
|
0.030x |
|
Vodafone Group Plc
F:VODJ
|
0.104x |
|
Kellanova
NYSE:K
|
0.117x |
|
Centene Corp
NYSE:CNC
|
0.167x |
|
Dover Corporation
NYSE:DOV
|
0.026x |
|
Chaozhou Three-circle Group Co Ltd
SHE:300408
|
0.041x |
|
Hannover Rück SE
F:HNR1
|
0.128x |
|
Teledyne Technologies Incorporated
NYSE:TDY
|
0.022x |
Annual Cash Flow Conversion Efficiency for Sandoz Group AG (2020–2025)
The table below shows the annual cash flow conversion efficiency of Sandoz Group AG from 2020 to 2025. For the full company profile with market capitalisation and key ratios, see Sandoz Group AG (SDZ) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CHF9.38 Billion ≈ $11.87 Billion |
CHF1.59 Billion ≈ $2.02 Billion |
0.170x | +111.37% |
| 2024-12-31 | CHF8.16 Billion ≈ $10.32 Billion |
CHF656.00 Million ≈ $829.36 Million |
0.080x | +113.76% |
| 2023-12-31 | CHF8.65 Billion ≈ $10.94 Billion |
CHF325.31 Million ≈ $411.28 Million |
0.038x | -100.00% |
| 2022-12-31 | CHF77.14K ≈ $97.52K |
CHF1.17 Billion ≈ $1.48 Billion |
15142.076x | +9097643.39% |
| 2021-12-31 | CHF7.44 Billion ≈ $9.40 Billion |
CHF1.24 Billion ≈ $1.57 Billion |
0.166x | +10.25% |
| 2020-12-31 | CHF6.83 Billion ≈ $8.63 Billion |
CHF1.03 Billion ≈ $1.30 Billion |
0.151x | -- |
About Sandoz Group AG
Sandoz Group AG develops, manufactures, and markets generic and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, supportive care, rare diseases, diabetes, immunology, endocrinology, neurology, osteoporosis, nephrology, hematology, and ophthalmology. It also provides a portfolio of ac… Read more